ImmunityBio Stock Sinks 20% as Revenue Misses Estimates Despite Bladder Cancer Trial Win and Israel Approval
ImmunityBio Inc. shares fell 20% after Q3 revenue of $48.84M missed estimates of $59.23M, despite a successful bladder cancer trial and Israel approval. The company reported a loss of 9 cents per share, wider than expected. Revenue grew 53% year-over-year but declined from the prior quarter. Anktiva, its lead product, saw expanded approvals and positive trial results.
How this was made
The 30-second read
Why it matters
The earnings miss outweighs the positive regulatory news, prompting a sharp share decline.
Market read
The earnings miss is the primary market-moving event; trial data offers a potential upside narrative.
What to watch
Rising R&D spend and convertible note accounting may have inflated loss figures.
Background
ImmunityBio announced FDA label expansion and Israel approval for Anktiva, while reporting a revenue miss.
Market effects
Biotech sector may see broader caution on revenue growth despite trial wins.
US biotech stocks could face short-term weakness.
Limited to investors in ImmunityBio and related oncology biotech peers.
Counterpoint
Trial success could underpin longer-term upside if future indications expand.
Key entities
- companyImmunityBio Inc.
Biotech firm developing Anktiva for bladder cancer.
